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Introduction
T-cell differentiation is characterized by the tightly regulat-
ed process of T-cell receptor (TCR) gene rearrangement, also
referred to as V(D)J recombination. V(D)J recombination in
TCR genes occurs in a precise order: TCRD, TCRG, TCRB,
TCRA.1 The V(D)J recombination process can be divided into
two different but equally important phases. In the first phase,
recombination activating gene (RAG) protein complexes con-
sisting of heterodimeric RAG1 and RAG2 proteins, recognize,
capture and bind recombination signal sequences (RSSs) that
flank V, D and J genes.2 Each RSS comprises a heptamer and
a nonamer sequence which are separated by either a 12 or 23
nucleotide spacer and recombine according to the 12/23 rule.3
Following capture of an RSS by the RAG complex, DNA dou-
ble-strand breaks (DSBs) are induced, resulting in coding ends
(CEs) that immediately form hairpins, and blunt signal ends
(SEs) that are rapidly fused into signal joints (SJs).2,4,5 The two
hairpinned CEs are kept closely together by the Ku70-Ku80
proteins that associate with the DNA-PKcs, which binds
Artemis. In the second phase, the DNA hairpins are nicked by
endonuclease activity of Artemis, followed by deletion of
nucleotides from the germline sequences and non-templated
insertion of de novo nucleotides by terminal deoxynucleotidyl
transferase (TdT),5 and, finally, by joining of the CEs into cod-
ing joints (CJs). The entire repair process is orchestrated by
components of the non-homologous end-joining (NHEJ)
pathway within the post-cleavage synaptic complex
(PCSC).4,5
Efficient recombination is restricted to recognition of RSSs
by the RAG proteins and the subsequent repair of RAG-
induced DSBs is confined to the PCSC. Despite these restric-
tions, molecular studies on translocation breakpoint (BP) sites
have provided proof of the involvement of the V(D)J recom-
bination machinery in the formation of aberrant recombina-
tions.5 Aberrant recombination between TCR genes and
oncogenes gives rise to chromosomal translocations that are
common in immature T-lymphoid malignancies, such as T-
cell acute lymphoblastic leukemias (T-ALL). These aberrant
recombinations result in juxtaposition of oncogenes in the
vicinity of TCR cis-acting regulatory elements such as
enhancers, or in removal of negative regulatory elements
(NRE) from the oncogene promoter.6 As a result, expression
of the involved oncogene, which often encodes for a tran-
scription factor, becomes deregulated. The deregulation of
the oncogene is considered to be an early key event in T-ALL
leukemogenesis.6 An overview of the TCR translocations,
translocation partners and occurrence in T-ALL is given in
Table 1.
Two TCR translocation mechanisms, designated as ‘Type
1’ and ’Type 2’, have been postulated.4,5 In ‘Type 1’ transloca-
tions, BP site sequences that are located outside the TCR loci,
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receptor chromosomal aberrations, such as SIL-TAL1 deletions, have likewise been recognized as V(D)J recombina-
tion associated aberrations. Despite the postulated role of V(D)J recombination, the extent of the V(D)J recombina-
tion machinery involvement in the formation of T-cell receptor and non-T-cell receptor aberrations in T-cell acute
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117 breakpoint sites from 22 different T-cell receptor translocation partners as well as 118 breakpoint sites from non-
T-cell receptor chromosomal aberrations. Based on this extensive set of breakpoint data, we provide a comprehensive
overview of T-cell receptor and oncogene involvement in T-ALL. Moreover, we assessed the role of the V(D)J recom-
bination machinery in the formation of chromosomal aberrations, and propose an up-dated mechanistic classification
on how the V(D)J recombination machinery contributes to the formation of T-cell receptor and non-T-cell receptor
aberrations in human T-cell acute lymphoblastic leukemia.
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Table 1. TCR-oncogene translocation occurrence in T-ALL.
Protein family Gene Chromosome band Chromosomal Occurrence References
Aberrations* in T-ALL
Basic helix-loop- helix TAL1 1p32 t(1;14)(p32;q11)/ ~4% (7, 8)
transcription factors (bHLH) t(1;7)(p32;q34)
TAL2 9q34 t(7;9)(q34;q34) ~2% (9)
LYL1 19p13 t(7;19)(q34;p13) ~7% (7)
OLIG2 21q22 t(14;21)(q11;q22) 2% (7)
MYC 8q24 t(8;14)(q24;q11) ~1% (7)
Lim only domain LMO2 11p13 t(11;14)(p13;q11)/ ~6% (6, 10)
(LMO) proteins t(7;11)(q34;p15)
LMO1 11p15 t(11;14)(p15;q11)/
t(7;11)(q34;p13) ~2% (11)
LMO3 12p12 t(7;12)(q34;p12) <1 (12)
Homeobox TLX1 10q24 t(10;14)(q24;q11)/ 5-10%C, ~30%A (13)
proteins t(7;10)(q34;q24)
TLX3 5q35 t(5;14)(q35;q11) 20-25%C,~5%A (14, 15)
HOXA cluster 7p15 t(7;14)(p15;q11)/ ~3% (14, 16)
inv(7)(p15;q34)
NKX2-1 14q13 t(7;14)(q34;q13)/ <1% (17), **
inv(14)(q13;q32)
NKX2-4 20p11 t(20;14)(p11;q11) <1% **
NKX2-5 5q35 t(5;14)(q35;q32) <1% (18)
Other NOTCH1 9q32 t(7;9)(q34;q34) <1% (19, 20)
CCND2 12p13 t(7;12)(q34;p13)/ <1% (21)
t(12;14)(p13;q11)
MYB 6q23 t(6;7)(q23;q34) ~3% (22)
LCK 1p34 t(1;7)(p34;q34) <1% (23)
BCL11B 14q32 inv(14)(q11;q32) <1% (24)
TCL1A 14q32 t(7;14)(q34;q32)/ <1% (25, 26)
inv(14)(q11;q32)
BMI1 10p12 t(7;10)(q34;p12) <1% (27)
*Chr.14q11: TCRD locus. Chr.7q34: TCRB locus.**Larmonie et al., unpublished data, 2013. CChildhood. AAdulthood.
and resemble RSSs (also referred to as cryptic RSSs;
cRSSs), are erroneously targeted by the RAG proteins. As
a result, non-TCR sequences are introduced into the V(D)J
recombination process and coupled to the TCR locus.5
‘Type 2’ translocations are formed, when DSBs at sites
devoid of cRSSs located within the oncogene locus, are
repaired and ligated to TCR genes during the V(D)J
recombination process via the NHEJ pathway.5 Non TCR-
associated chromosomal aberrations such as deletional
aberrations (SIL-TAL1) and insertions (HPRT1) have also
been appointed as V(D)J recombination-mediated events
based on the presence of cRSSs at BP sites.28-31
Until now, TCR-associated translocation mechanisms
have mainly been evaluated for only a few BP sites by
means of ex vivo experiments,4,6,31,32 basically confirming
the concept of RAG mistargeting to cRSSs. These onco-
genes and their respective BP sites were usually chosen for
their high frequency in T-ALL and also because of the
probability that they would function as a cRSS based on
structural criteria.32
Despite the postulated role of V(D)J recombination, it is
still not clear to what extent the V(D)J recombination
machinery is mechanistically involved in the formation of
TCR and non-TCR aberrations in T-ALL. Here we exam-
ined 117 molecularly defined BP sites and their sequences
from 22 different TCR translocation partners as well as
118 BP sites from non-TCR aberrations in our T-ALL
cohort and T-ALL cases described in literature. Based on
this large and comprehensive in silico and ex vivo evaluation
of BP sites, on analysis of TCR loci and oncogene involve-
ment, and on analysis of pre- and post-translocation con-
figurations of the TCR translocations, we critically re-
evaluated the role of the V(D)J recombination machinery
in the formation of chromosomal aberrations.
LMO2, TAL1, and TLX1 are the predominant 
TCR translocation partners and show clear 
translocation BP clusters
In the 117 TCR translocations evaluated, a total of 22 dif-
ferent oncogenes were identified as TCR translocation
partner. LMO2 (15%), TAL1 (11%), and TLX1 (25%) loci
were most frequently involved in these translocations,
while other TCR translocation partners were less frequent-
ly observed (approx. 32% of total, and each <5%) (Table 2
and Online Supplementary Table S2). The translocation fre-
quencies reported here are based on the available molecu-
lar data, and may, therefore, not reflect true prevalence of
these oncogenic TCR translocations in T-ALL.
Translocation BP sites in the LMO2, TAL1 and TLX1 loci
appeared to be localized in distinct regions and were either
densely clustered in breakpoint cluster regions (BCRs;
defined as more than two BP sites within a region of 50 bp
from each other, and sharing a common translocation DSB
type) or localized as single BP sites (Figure 1, Table 2, and
Online Supplementary Table S2). The LMO2 locus has two
distinct BCRs (hereafter referred to as BCR1 and BCR2),
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with approximately 40% (7 of 17) of the BP sites located in
a BCR. Approximately half (6 of 13) of the TAL1 BP sites
and 67% (33 of 49) of the TLX1 BP sites formed a BCR
(Figure 1). LMO2, TAL1 and TLX1 BCRs localize in the
direct vicinity of a transcription starting site (TSS), at the
5’-end of the coding region of the gene while, in contrast,
the TAL2 BCR localized at the 3’-end of the oncogene. The
localization of BCRs in the vicinity of a TSS suggests a
localized accessibility at these sites, presumably as a con-
sequence of transcription activity that in turn is associated
with a bias towards mutation formation.67 The majority
(approx. 90%) of the BP sites are found outside of the cod-
ing regions of the genes, with approximately 65% being
localized at the 5’-end of the gene and approximately 25%
at the 3’-end, while approximately 10% are localized with-
in the coding regions (Figure 2A). This indicates that the
localization of a translocation BP site, particularly the BCR,
is oncogene-specific, which is most likely associated to the
selective advantage gained from the translocation, depend-
ent on the function of the transformed gene. Even though
the exact position of the BP site within the coding region
of the oncogene locus and the resulting selective advantage
ultimately determine whether the outcome of a transloca-
tion will be the development of a T-ALL, this still does not
explain why specific BP sites become recurrently involved
in aberrations while others do not.
Table 2. Oncogene, TCR locus and translocation type involvement in 117 TCR translocations BP sites.
Gene BP Distance to TSS Evaluated cases TCR involvement Translocation type Reference
(region) (nt) (n) (n) (n)
TCRD TCRA TCRB Type 1* Type 2
LMO2 5’of BCR2 -6,902/-5,654 2 2 0 0 1 1 (6, 33)
BCR2 -1,849/-1,846 3 3 0 0 0 3 (6)R
5’of BCR1 -1,659 2 1 0 1 0 2 (6, 33)
BCR1 -384/-392 4 4 0 0 4 0 (6, 34, 35)
3’of BCR1 +169/+34,160 6 6 0 0 3 3 (6, 36, 37)R
17 16 0 1 8 9
TAL1 5’of BCR -3,208/-817 3 3 0 0 0 3 (38-40)R
BCR +427/+431 6 6 0 0 6 0 (38, 40, 41)
3’of BCR + 10,780/+53,085 4 3 0 1 1 3 (42-45)
13 12 0 1 7 6
TLX1 5’of BCR - 11,129/-3,158 6 4 0 2 1 5 (46-48)
BCR -509/+19 35 35 0 0 0 35 (46, 49-50)
3’of BCR +1,313/+30,539 8 1 0 7 2 6 (30, 46, 51)
49 40 0 9 3 46
BCL11B n.a +48,651i 1 1 0 0 0 1 (24)
BMI1 n.a. -277,473 1 0 0 1 0 1 (27)
CCND2 n.a. - 61,328 1 0 0 1 1 0 (21)
MYB n.a. +53,891/+53,903 2 0 0 2 0 2 (22)
+144,584 1 0 0 1 1 0 (22)
HOXA6 n.a. -2,179 1 1 0 0 0 1 (16)
HOXA9 n.a. -2,992/-501i 2 0 0 2 0 2 (12, 52)
LCK n.a. +20,253/+25,085 2 0 0 2 1 1 (23, 53)
LMO1 n.a. -9,644 1 1 0 0 0 1 (54)
-5,258 2 2 0 0 2 0 (10, 55)
LMO3 n.a. +224,944 1 0 0 1 0 1 (12)
LYL1 n.a. +8,444 1 0 0 1 0 1 (54)
+787 1 0 0 1 0 1 (56)
MYC n.a. +5,96/+10,318 4 0 4 0 1 3 (57-60)
+239,565 1 1 0 0 0 1 (58-61)
NKX2-1 n.a. +4,286 2 1 0 1 0 2 (17)
NKX2-4 n.a. -494 1 1 0 0 0 1 Current Study
NKX2-5 n.a. +35,271 1 1 0 0 0 1 (18)
NOTCH1 n.a. +39,552/+42,969 5 0 0 5 2 3 (19, 62, 63)
OLIG2 n.a. +84,224 1 0 1 0 0 1 (64)
TAL2 n.a. + 31,795/+31,766 3 0 0 3 3 0 (65)
TCL1A n.a. -145,630/-99,998i 2 0 1 1 0 2 (25-26)
TLX3 n.a. -50,034 1 1 0 0 0 1 (66)
38 10 6 22 11 27 -
Total 117 78 6 33 29 88 -
*Based on cRSS functionality determined by in silico and/or ex vivo analysis. iInversion; n.a.: not applicable. RSequences found in the GenBank database. 
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TCR translocations in T-ALL mostly involve 
the TCRD locus
The majority (approx. 67%) of all TCR translocations
involved the TCRD locus. Approximately 94% of LMO2,
92% of TAL1, and 82% of TLX1 translocations occurred
during an attempted TCRD gene rearrangement (Figures 1
and 2A, and Online Supplementary Table S2). The BP sites
associated to the TLX1 BCR exclusively concerned TCRD
translocations, while all BP sites located at the 3’-end of
the TLX1 exon 3 exclusively involved the TCRB locus
(Figure 1). Approximately 58% of BP sites of the less fre-
quent T-ALL TCR translocation partners translocated to
the TCRB locus (Figure 2B). Interestingly, particular onco-
genes have been observed to almost exclusively translo-
cate with a specific TCR locus (Tables 1 and 2).
Considering this exclusivity, and the fact that TCR loci
recombine at specific stages of thymocyte development,
one could hypothesize that synchronous accessibility of a
specific oncogene locus and the TCR locus may play an
important role in determining specific oncogene-TCR
locus interactions and translocation probability during
V(D)J recombination. In addition, since the actual physical
contact between translocation partners is required for the
eventual formation of a translocation, it is likely that the
probability of translocation is likewise determined by
nuclear proximity.
Analysis of the location of the BP site in relation to the
TCR locus involved in the translocation showed that
approximately 82% of all TCRD translocations involved
the 5’-end of the oncogenes, while 5’-regions of oncogenes
were involved in only approximately 36% of the TCRB
translocations (Figure 2A). The observed prevalence of
TCRD involvement at the 5’-end of oncogenes, together
with the high frequency of TCRB translocations (approx.
49%) at the 3’-end of oncogenes, agrees with the theory of
oncogenic regulation being dependent on the actual TCR
locus involved.46,68 The high prevalence of TCRD associat-
ed translocations, and the association of the BP sites
involved with specific oncogene regions, suggests a partic-
ular proneness of the TCRD locus for aberrant recombina-
tions and/or a selective leukemogenetic advantage upon
involvement of the TCRD locus in translocations. While
the majority of translocations (approx. 67%) involve the
TCRD locus, TCRA was only involved in approx. 5%
(n=6) of the translocations and exclusively concerned
TCL1A, OLIG2 and MYC translocations. TCRG locus
involvement was not observed in any of the translocations
analyzed and has so far never been reported in TCR
translocations in T-ALL. The lack of TCRG translocations
is remarkable, as most reported trans-rearrangements
(inter-TCR gene rearrangements) do involve the TCRG
locus,69,70 suggesting that the locus can be implicated in
N.S.D. Larmonie et al.
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Figure 1. Overview of
T-ALL associated BP
position and cRSS in
LMO2, TAL1 and TLX1
locus. The position of
every BP analyzed in
this study is given for
LMO2, TAL1 and TLX1
respectively. For each
BP, the associated
cRSS is given.
Positions of the most
upstream and most
downstream BP are
given relative to the
TSS. Breakpoint clus-
ter region (BCR) (a
region containing >2
BP sites with ~50bp
between adjacent BP
sites).
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aberrant V(D)J rearrangements. It has been shown that in
TCRB translocations, the TCRB enhancer is involved in
driving the oncogene, whilst in TCRD translocations,
oncogenic expression is mostly driven by the TCRD inter-
nal promoter.68 Interestingly, the TCRG locus carries both
enhancer and silencer sequences. Signaling via the pre-
TCR, which plays a role in T-ALL development,71 can acti-
vate the TCRG silencer.72 The apparent lack of TCRG
translocations in T-ALL could thus be the result of pre-
TCR mediated activation of the TCRG silencer located in
cis of the TCRG locus that was involved in a translocation,
resulting in dampening of oncogenic activation. It might
well be that the positive and negative selection phases of
TCRαβ thymocytes are implicated in the low occurrence
of TCRA locus translocations seen in T-ALL. TCRA
translocations are formed at the latest thymocyte develop-
mental stage. It is reasonable to think that upon transloca-
tion, the window for acquiring additional mutational hits
is small, thus limiting the chance for tumorigenic transfor-
mation. Since the majority (>90%) of the TCRαβ thymo-
cytes do not survive selection but undergo apoptosis, the
majority of the TCRA translocations will, therefore, be
lost.
TCR gene involvement discloses window 
of translocation occurrence
Analysis into TCRD gene involvement showed that
approximately 42%, 28% and 28% of the TCRD translo-
cations occurred during an attempted Dδ-Dδ, Dδ-Jδ or Vδ-
Dδ recombination, respectively, indicating a preference for
aberrant recombinations to occur during Dδ-Dδ rearrange-
ments. The TCRB translocations predominantly (approx.
76%) occurred during Dβ-Jβ recombinations, whilst only
approximately 17% of the translocations occurred during
Vβ-Dβ recombination. Five of the TCRA translocation
events were formed during attempted Vα-Jα recombina-
tions, and in one case, the translocation seemed to have
occurred during simultaneous induction of DSBs at two Jα
genes. It should be noted that oncogenic transformation
might not manifest at the exact stage in which transloca-
tion occurs, but rather at a later developmental stage,7 usu-
ally after acquisition of subsequent mutational hits.73
Since most of the TCRD and TCRB translocations
involved the Dδ and Dβ genes, respectively, this would
suggest an increased chance for the occurrence of an erro-
neous recombination during the earliest phases of TCRD
and TCRB recombination. These findings show that the
window of opportunity for translocation formation from
the perspective of the TCRD locus is mainly during the
DN stages of thymic development (Dδ-Dδ, Dδ-Jδ recom-
binations), whereas the TCRB locus is most likely
involved in translocations during the ISP and DP3- stages
of thymocyte development (Dβ-Jβ recombinations)1
(Figure 3). However, based on the relative occurrence of
TCRD and TCRB translocations and the high frequency of
Dδ-Dδ miscoupling in T-ALL, we conclude that, overall,
the majority of TCR translocations most likely occur dur-
ing attempted Dδ-Dδ recombinations, in the DN1 and
DN2 developmental stages (Figure 3).
TCR translocations in T-ALL are mostly formed via 
the ‘Type 2’ translocation pathway
In silico testing of the 117 BP sites based on recombina-
tion information content (RIC) threshold scores (see
Online Supplementary Design and Methods) identified a cRSS
at only 27 BP sites (23%) that were found within the
LMO2, TLX1, TAL1, TAL2, MYC, NOTCH1, LMO1, C-
MYB and LCK oncogene loci (Table 2, Online
Supplementary Table S2). Ex vivo studies in our laboratory
confirmed that BP sites associated to TLX1, LMO1,
LMO3, and LYL1 that were devoid of a cRSS were not
induced by RAG (Online Supplementary Table S3), thus sup-
V(D)J recombination role in (non) TCR aberrations
haematologica | 2013; 98(8) 1177
Figure 2. Pie charts illus-
trating percentages of
TCR and oncogene
translocation occurrence
in T-ALL. (A) Pie charts
illustrating percentages
of BP site localization rel-
ative to the functional
regions of the oncogenes
involving all BP sites or
involving a particular
TCR locus. (B) Pie charts
illustrating percentages
of TCRD, TCRB, and TCRA
related translocations
involving LMO2, TAL1,
TLX1 and the rest of the
analyzed translocation
partners.
A
B
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porting the idea that translocations involving these sites
were formed via the ‘Type 2’ translocation pathway. This
further confirmed our previous findings of a high correla-
tion between the RIC score obtained from in silico analysis
and the translocation efficiency determined by means of
ex vivo recombination substrate assay.6 Only approximate-
ly 25% of the whole spectrum of TCR translocations in
human T-ALL is driven by RAG mistargeting of cRSSs
(‘Type 1’ translocations). Interestingly, a large fraction
(approx. 36%, 16 of 78) of the TCRB translocations
occurred via the ‘Type 1’ translocation pathway, while this
was the case for only approximately 21% (12 of 33) of
TCRD translocations and approximately 17% (1 of 6) of
TCRA translocations (Figure 4A). In approximately 75%
of cases, the involvement of the V(D)J recombination
machinery is mainly apparent due to the involvement of a
TCR locus in these formations. This reinforces previous
notions based on smaller series that TCR translocations
predominantly occur via the ‘Type 2’ translocation path-
way.5,32 Furthermore, this suggests that the V(D)J recombi-
nation machinery per se is not the driving force in the
induction of DSBs at the majority of the BP sites that lead
N.S.D. Larmonie et al.
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Figure 3. Window of
opportunity for formation
of TCRD and TCRB locus
translocations. Schematic
overview of consecutive
stages of normal human
thymocyte development.
Graphs show rearrange-
ment activity (%) during
each developmental
stage. The arrows indicate
the window in which each
recombination/ transloca-
tion combination can
occur. V(D)J recombina-
tion graphs are adapted
from Dik et al.1 DN: dou-
ble negative; ISP: imma-
ture single positive; DP:
double positive; SP: single
positive.
Figure 4. Pie charts illustrating
percentages of translocation
type. (A) Percentages of the
occurrence of ‘Type 1’ and
‘Type 2’ translocations involv-
ing the TCRD, TCRB, and TCRA
genes. (B) Percentages of ‘Type
1’ and ‘Type 2’ translocations
involving either LMO2, TAL1,
TLX1 and the remaining
translocation partners.
A
B
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to TCR translocation formation.
TLX1 associated translocations are mostly governed by
the ‘Type 2’ translocation pathway. Contrary to current
assumptions, 3 (6%) of the TLX1 translocations seem to
have resulted from the ‘Type 1’ translocation, as these BP
sites are associated with functional cRSSs as defined by in
silico analysis based on RIC threshold levels. Interestingly,
these three cRSS-related TLX1 translocations are all
TCRB-associated translocations (Figure 1). Importantly,
the TLX1 BCR and LMO2 BCR2 did not associate to a
cRSS, while both the LMO2 BCR1 and the TAL1 BCR
translocations did. Other translocation partners mostly
(>71% of cases) translocated via the ‘Type 2’ transloca-
tion pathway (Figure 4B). This clearly shows that the
majority of TCR translocations are not caused by RAG-
cRSS interactions. The presence of a cRSS at a BP site is
the most obvious genetic feature known to render DNA
susceptible to DSB induction involved in TCR transloca-
tions. The fact that the TLX1 BCR and the LMO2 BCR2
are not associated to a cRSS suggests that these sites must
be associated with another type of sequence-specific fea-
ture rendering these particular sites recurrently suscepti-
ble to DSB inductions.
cRSSs in oncogene loci are not randomly involved 
in T-ALL translocations
cRSSs are distributed throughout the entire human
genome at an average density of one cRSS per 500 bp.74
The LMO2 locus comprised 109 cRSS, of which only 5
(<4%) were associated with a BP site. The 12 bp spacer
cRSS with the highest RIC score (-29.21) was identified at
the LMO2 BCR1. Interestingly, the 23 bp spacer cRSS with
the highest RIC score (-48.74) was not associated to any of
the LMO2 BP sites in our study, while the position and ori-
entation of this cRSS could have caused the oncogenic
activation of LMO2 upon involvement in a translocation
(Online Supplementary Figure S1). Of the 56 cRSSs identi-
fied in TAL1, the TAL1 BCR did associate to its most effi-
cient 23 bp spacer cRSS (RIC score: -46.34), while no BP
sites were associated to the 12 bp spacer cRSS with the
highest RIC score (-31.10). Of the 139 TLX1 cRSSs identi-
fied, the UPN474 BP site was associated to the most effi-
cient 23 bp spacer cRSS (RIC score: -47.754), while no BP
sites were associated to the 12 bp spacer cRSS with the
highest RIC score (-29.66). Interestingly, the TLX1 and
LMO2 12 bp spacer cRSSs as well as the TLX1 and TAL1
23 bp spacer cRSS have comparable RIC scores, implying
V(D)J recombination role in (non) TCR aberrations
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Table 3. Determination of RAG involvement at BP sites involved in non-TCR chromosomal rearrangements.
Mutation Oncogene Distance to In silico determined RIC Fusion Distance to In silico determined RIC Reference
gene TSS cRSS present at BP score partner TSS cRSS present at BP score
Deletion
SIL-TAL1 TAL1 -2.109/-2.129* CACAGCC-23-AAGGAAAAG -46.62 SIL +396/+420* no - (8, 29, 39, 97)
-3.792/-3.802* CACAGAG-12-GCCAAAACT -28.12 +405/+420* no - (8, 97)
+5.292* CACACAC-12-GATAGAAAC -38.63 +407* no - (8)
CACACAC-23-ATAGAAACA -50.05
-2.190* CACAGCC-23-AAGGAAAAG -46.62 +1.067* no - (97)
-6.187* no - +407* no - (97)
LMO2-RAG2 LMO2 +2,687* no - RAG2 +3,110* no - (98)
-31,943* no - -71,278* no - (98)
Insertion/
Deletion
HPRTA +687* CAGTGTG-23-GGCAAAACC -36.92 RSSVα24/ nd CACAGTG-23-ACGCAAACC -27.57 (28, 30)
RSSJα29(ins.) /CACAGTG-23-ACTCAAACC /-27.83
HPRT1 nd nd nd RSSVα22/ nd/nd CACAGTG-23-ACACAAACC / -25.91 (30, 96)
Deletions/ RSSJα45(ins.) CACTCTG-12-ACATAAACT /-23.23
Insertions nd/ nd/nd nd/ RSSVα34/ nd/nd CACAGCG-23-CTCCAAACC -39.11 (30, 96)
nd nd RSSJα44(ins.) /CACTGTG-12-ACAGAAACC /-21.54
+684 CAGTGTG-12-GGCAAAACC/ -36.92 BICD1 +7,693/ -/ -56.46 (28, 30)
/+20.693(del)*B CACACAC-12-ACAAATACA -28.28 (ins.)(del)B +8,282* CAAAGTG-23-TGCGCCCGG
33,400/33,422 no - - - - - (95)
33,359/23,551 no - - - - - (95)
11,405/17,892 no - - - - - (95)
22,664/29,064 no - - - - - (95)
13,588/26,981 no - - - - - (95)
HPRT1 14,949/27,861 no - - - - - (95)
Deletions 1,980/28,526 no - - - - - (95)
23,322/27,499 no - - - - - (95)
13,092/13,447 no - - - - - (95)
+667/+679 (n=15) CAGTGTG-12-GGCAAAACC -36.92 - +20,658 CACACAC-12-ACAAATACA/ -28.28 (99)
/+20,679 CACACAC-23-TTTGTGTGT -57.793
+672/+677 CAGTGTG-12-GGCAAAACC -36.92 - +18,581 CACACAC-12-TCTTAATCC -36.19 (99)
(n=2) /+18,590 CAGAGAG-23-TAAAAAGTG -63.91
+678 (n=1) CAGTGTG-12-GGCAAAACC -36.92 +20,998 - - (99)
AHPRT1 associated insertions shown are mutations found in normal human T cells, *The precise BP position is not known due to type of break, No: no functional cRSS found at that BP posi-
tion according to the RIC algorithm analysis., -: no RIC score, nd: not determined, X/Y(del): Deletion between 5’BP and 3’BP position, X(ins.):Insertion of that particular sequence in to another
locus. BThe presence of a cRSS tested at both BP sites.
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similar recombination efficiency. However, none of these
TLX1 cRSSs are associated to a TLX1 BCR, even though
they are located within a region (at the 3’end of the TLX1
locus) known to be involved in translocations (Online
Supplementary Figure S1). These observations imply that
particular cRSSs involved in T-ALL translocations are pref-
erentially targeted over other highly efficient cRSSs found
within the same region and that particular cRSSs do not
become engaged in T-ALL translocations, whilst other BP
sites in the vicinity of these allegedly highly recombina-
tion efficient cRSSs are associated to non-RAG-cRSS
mediated breaks. Moreover, this shows that the targeting
of cRSSs for involvement in a T-ALL translocation is not
random and is independent of the recombination efficien-
cy of a cRSS, implying that other (genetic or epigenetic)
factors are eventually decisive for break susceptibility at
these particular sites.
The role of the V(D)J recombination machinery 
in DSB induction and aberrant repair leading 
to TCR translocations
Ex vivo experiments have clearly proven the ability of
RAG to bind and cleave cRSSs. However, our observations
clearly indicate that cRSSs are not randomly targeted by
RAG in vivo. It is well known that chromatin organization
influences the ability of RAG to gain access to an authentic
RSS.75 Therefore, access to a cRSS is also decisive for the
occurrence of RAG-cRSS mistargeted DSB induction at
oncogene loci sites. Reactivity of the RAG protein com-
plex is not only dependent on the recognition of a cRSS by
RAG1, but it is likewise dependent on the ability of RAG2
to bind to a H3K4me3-modified nucleosome adjacent to
that cRSS in order to enable cleavage at that cRSS site.76
This suggests that epigenetic marks at a cRSS in the onco-
gene locus must be optimal to enable RAG-cRSS recogni-
tion and subsequent cleavage. Since epigenetic marks are
site-specific, they can mediate heterogeneous accessibility
throughout the locus. This differential accessibility could
(at least in part) be the cause for a preferential involvement
of particular cRSSs in TCR translocations. 
Besides being a sequence-specific nuclease targeting
(c)RSSs, RAG protein complexes are also able to function
as a structure-specific nuclease, recognizing non-B DNA
structures as substrate.77,78 The ability of RAG to induce
DSBs at non-B DNA structures suggests that RAG could
be involved in a broader range of DSB induction mecha-
nisms and thus be the driver of DSB inductions involved
in ‘Type 2’ translocations.78,79 This means that non-cRSS
associated DSB inductions could still be RAG mediated,
thus providing a new perspective on ‘Type 2’ transloca-
tions. This would also imply that RAG associated translo-
cations do not only occur in the 25% ‘Type 1’ aberrations
but do, in fact, occur more often. Other sequence-specific
features (transposable elements, association with origin of
replication, GC-content or free energy levels80-82) could also
be involved in making these ‘Type 2’ sites more suscepti-
ble to DSB induction, on top of the vulnerability level pro-
vided by a cRSSs or by the DNA conformational suscepti-
bility. 
Particular RAG mutations have been shown to cause the
formation of unstable RAG post-cleavage synaptic com-
plexes (PCSC) that allow DSBs to participate in the error-
prone alternative NHEJ repair pathway.83 Although we do
not have any indications about this, we cannot formally
exclude the possibility that such RAG mutations could be
the cause of the T-ALL derived translocations that we
evaluated. However, identification of pre- and post-
translocation TCR recombination configurations of
derivate chromosomes, as seen in T-ALL, provides evi-
dence that RAG proteins are able to initially target an
authentic RSS prior to mistargeting a cRSS in ‘Type 1’
translocations. Furthermore, such analyses also show that
correct joining of CEs within the same cell is possible prior
to or subsequent to ‘Type 2’ translocation formation.
Ongoing recombination following the translocation event
is a phenomenon that has been previously described for
TAL2 translocations and that is thought to contribute to
the post-translocation oncogenic effect.84,85 The fact that
normal recombination can precede or follow a transloca-
tion event in the very same cell implies that nothing is
intrinsically wrong with the V(D)J recombination machin-
ery in these aberrant cells.
Irrespective of the ability of RAG to induce DSB at
either cRSS sites, or DNA structures similar to non-canon-
ical (non-B) DNA structures, or other sequence-specific
features,77 the question remains whether RAG-induced
DSBs actually stimulate translocation formation. RAG-
cRSS complexes have been shown to cause PCSC instabil-
N.S.D. Larmonie et al.
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Table 4. Conditions to determine the involvement of the V(D)J recombination mechanism in the formation of chromosomal aberrations and to
define the aberration type.
V(D)J recombination TCR cRSS Condition Frequency* Typical
associated aberration involvement involvement aberrations
Type
Type 1A + + TCR locus with RSS locus with cRSS ~14% TCR-LMO2
AND
Type 1B** - + locus with cRSS locus with cRSS - HPRT1-BICD**
AND
Type 2A + - TCR locus with RSS locus without cRSS ~40% TCR-TLX1
AND
Type 2B - + locus with cRSS locus without cRSS ~40% SIL-TAL1
AND (frequent)
Type 3*** - - locus without cRSS locus without cRSS ~2% SIL-TAL1
AND (rare types)
*Percentages based on both TCR translocation and non-TCR molecularly defined aberrations in T-ALL analyzed in this study, **so far not (yet) identified in T-ALL, ***with untem-
plated nucleotides at junctional regions, :RSS,  :cRSS,  : no cRSS. 
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ity, which in turn inhibits repair at these sites via the clas-
sical homologous recombination pathway86 and promotes
repair via the alternative NHEJ pathway. Since RAG pro-
tein-complexes are known to ‘shepherd’ broken ends into
the NHEJ repair pathway,87 off-target RAG-induced DSBs
could be more prone to involvement in the DSB repair
process at the V(D)J recombination site. Such susceptibili-
ty to repair-mistakes and translocations has also been
observed in patients with the repair deficiency syndromes
Nijmegen breakage syndrome (NBS) (NBN gene) and atax-
ia telangiectasia (AT) (ATM gene).88,89 Even though ATM-
deficient mice have been shown to carry an increase in
TCRD/A translocations,90,91 it should be stressed that this
proneness to translocations only causes a generalized
defect in the damage response upon DSB acquisition, and
does require RAG activity for actual induction of translo-
cations involving the TCR loci.92
The involvement of the V(D)J recombination mechanism
can be extended to non-TCR and non-cRSS associated
aberrations 
Involvement of the V(D)J recombination machinery in
the formation of TCR translocations in T-ALL is clearly
evident, particularly when considering the involvement of
the TCR genes in these aberrations. However, V(D)J
recombination activity in T-ALL is not limited to
rearrangements involving TCR loci given that cross-lin-
eage Ig gene rearrangements (mainly involving IGH) have
been observed in low frequencies as well.93,94 The attribu-
tion of the V(D)J recombination machinery in the forma-
tion of other, non-TCR related chromosomal aberrations
in T-ALL is, however, less evident. We analyzed 118 BP
sites of non-TCR associated aberrations observed in T-
ALL by determining the presence of cRSS at the different
BP sites and evaluated the potential role of the V(D)J
recombination mechanism in the formation of these aber-
rations. HPRT1 related insertions, though not directly
implicated in T-ALL leukemogenesis, do occur in normal
peripheral T-lymphocytes.28,30,95 Even though these inser-
tions do not seem to have direct oncogenic effect, we did
analyze them to delineate the mechanism involved.
HPRT1 has frequently been shown to carry a complex
deletion/insertion rearrangement, where gross regions of
the TCRA locus are inserted into the HPRT1 locus.28,30,96
One of the three TCRA insertions identified in this study
(the BP site of 2 other cases could not be identified)
showed involvement of a cRSS at the HPRT1 locus (Table
3). A BICD insertion (9q22) into HPRT1 locus has also
been described. In this case, both ends of the HPRT1 BP
sites carried a cRSS, while only one end of the inserted
BICD sequence carried a cRSS. In addition to insertions,
deletions are also common in the HPRT1 locus. Analysis of
the different BP sites showed that the BCRs related to the
HPRT1 deletions are associated to a cRSS; however, in
approximately 50% of the deletions, no cRSSs could be
identified at the deletion BP sites (Table 3).
Analysis of BP sites of SIL-TAL1 deletions (del(1p))
showed that approximately 99% (84 of 85) of all TAL1 BP
sites are associated with a cRSS whilst, in contrast to ear-
lier suggestions,31,32 none of the SIL BP sites tested had a
cRSS in their vicinity (Table 3). Although TAL1 also fre-
quently translocates to TCR loci, interestingly none of the
TAL1 BP sites involved in SIL-TAL1 deletions were in the
direct vicinity of the TAL1 BP sites involved in TCR
translocations. The single SIL-TAL1 case that lacked
involvement of a cRSS at either of the BP sites, did have
eight untemplated nucleotides at the junctional region,97
suggesting the presence of TdT activity during ligation of
these BP sites.
The cryptic deletion del(11)(p12p13) fuses the LMO2
gene to the RAG2 gene.98 No cRSS was identified at the
RAG2 or LMO2 BP sites. However, a potential untemplat-
ed nucleotide is present at the junctional region (Table 3).
Despite the high occurrence of LMO2 in TCR transloca-
tions, LMO2 deletional BP sites do not co-localize with BP
sites associated in LMO2-TCR translocations. We previ-
ously showed that LMO2 activation was associated with
the loss of the LMO2 negative regulatory element (NRE)
rather than due to juxtaposition of LMO2 to the TCRD
enhancer.6 Furthermore, we identified the presence of one
12 bp spacer cRSS 3’ of the LMO2NRE and three different
23 bp spacer cRSSs at the 5’ side (Online Supplementary
Figure S2).6 Since many T-ALL cases have unresolved
LMO2 activation, and these cRSS lay in the orientation for
RAG-mediated NRE deletion (Online Supplementary Figure
S1A), we determined the mutual recombination potential
of these cRSSs. To this end, the ability of these cRSS to
mediate a deletion ex vivowas tested by means of a recom-
bination substrate assay (Online Supplementary Appendix).
The ex vivo analyses showed that none of the 12 bp / 23 bp
cRSS combinations tested (Online Supplementary Table S4
and Figure S2A) invoked such recombination.
Nevertheless, the HPRT1(-BICD1) deletions/insertions
show that interactions between cRSSs can occur.28,30 Even
though such cRSS-cRSS interactions have not yet been
identified in T-ALL, involvement of the V(D)J recombina-
tion machinery in the formation of these aberrations is
evident based on the presence of cRSSs at the BP sites and
the insertion of untemplated nucleotides at the junc-
tions.28,30
Comprehensive classification of TCR and non-TCR 
aberrations with respect to the role of the V(D)J
recombination mechanism
Collectively, our findings indicate that the V(D)J recom-
bination mechanism can also be involved in non-TCR
aberrations, and in particular cases, potentially even in
non-cRSS associated aberrations. Despite the fact that
cRSS-cRSS interactions have not been observed in T-ALL
so far, they are comparable to ‘Type 1’ (RSS-cRSS) recom-
binations. Hence, we propose that these cRSS-cRSS
recombinations be denoted ‘Type 1B’ recombinations in
which a second cRSS replaces the authentic TCR RSS
(Table 4). Analogous to TAL1 translocations, the V(D)J
recombination machinery is also involved in SIL-TAL1
deletions,31 as deduced from the presence of cRSSs at the
TAL1 deletion BP sites only. The addition of random
nucleotides at these junctions, a TdT-driven hallmark of
the V(D)J recombination process, further confirms this
involvement. Notably, it cannot be excluded that DNA
polymerase mu (Polμ) can also be involved next to TdT.100
The lack of cRSSs at the SIL BP sites however, suggests
that, similar to ‘Type 2’ translocations, non-RAG induced
DSBs within SIL are repaired via the NHEJ pathway with-
in a RAG synaptic complex. This could be indicative of a
variant of the ‘Type 2’ recombination pathway. In this
proposed ‘Type 2B’ aberration (Table 4 and Online
Supplementary Figure S3) TAL1 would act as the carrier of
the cRSS instead of the authentic TCR RSS. Although not
as obvious, a role for the V(D)J recombination machinery
V(D)J recombination role in (non) TCR aberrations
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could also be argued in cases such as SIL-TAL1 and LMO2-
RAG2 deletions97,98 that, despite the lack of a cRSS at the
reciprocal BP sites, do show potential non-templated
nucleotides at the junctions. Such recombinations could be
tentatively referred to as ‘Type 3’ aberrations (Table 4).
Conclusions
The activity of the V(D)J recombination machinery in
thymocytes is primarily limited to the TCR locus. This
restriction is determined by an interplay of sequence-spe-
cific features and TCR locus accessibility. As this process
is confined to PCSCs, this, in principle, ensures the main-
tenance of genome stability. Nevertheless, it is clear that
the V(D)J recombination machinery is involved in the for-
mation of genomic aberrations by mediating DSB induc-
tion and erroneous repair of breaks in non-TCR loci during
the recombination process. Here we demonstrate that
only approximately 25% of the whole spectrum of TCR
translocations in human T-ALL is driven by RAG mistar-
geting of cRSSs (‘Type 1’ translocations). In approximately
75% of cases, the involvement of the V(D)J recombination
machinery is mainly apparent due to the involvement of a
TCR locus in these formations (‘Type 2’ translocations).
Non-TCR chromosomal aberrations in T-ALL do not
involve RAG mistargeting either, with the exception of
SIL-TAL1 deletions, which can be considered as a ‘Type
2B’ aberration (Online Supplementary Figure S3). Thus,
V(D)J recombination associated aberrations mostly result
from repair mistakes rather than RAG mistargeting of
cRSS. Furthermore, our findings argue that nothing is
intrinsically wrong with the V(D)J recombination mecha-
nism in these T-ALL, since pre- and post-translocation
chromosome configurations indicate normal RAG target-
ing, repair and recombination of the involved TCR locus
in the same cell.
Collectively, our results suggest that the V(D)J recombi-
nation machinery is generally not the driving force in the
onset of the formation of TCR translocations and other,
non-TCR genetic aberrations in human T-ALL. Rather it
appears to play a role in facilitating the formation of these
aberrations through repair, following any type of DSB
breaks in particular oncogene regions. Based on these find-
ings, we propose an extended and comprehensive mecha-
nistic classification scheme on how the V(D)J recombina-
tion machinery contributes to TCR-associated and non-
TCR associated aberrations in T-ALL (Table 4). When con-
sidering the frequency of cRSS associated versus non-cRSS
associated aberrations using this new classification, we
see that approximately 50% of the chromosomal aberra-
tions in T-ALL as evaluated here are cRSS-mediated (Table
4). This is a considerably higher frequency of cRSS-medi-
ated DSB inductions leading to chromosomal aberrations
than previously thought.
Acknowledgments
The authors would like to thank Sandra de Bruin-Versteeg for
preparing the figures and Albert van de Maat for help in cloning
and testing translocation BPs.
Funding
This work was supported by the Mozaïek (Mosaic) grant
017.004.089 from The Netherlands Organisation for Scientific
Research to NSDL. 
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
N.S.D. Larmonie et al.
1182 haematologica | 2013; 98(8)
References
1. Dik WA, Pike-Overzet K, Weerkamp F, de
Ridder D, de Haas EF, Baert MR, et al. New
insights on human T cell development by
quantitative T cell receptor gene rearrange-
ment studies and gene expression profiling. J
Exp Med. 2005;201(11):1715-23.
2. Schatz DG, Ji Y. Recombination centres and
the orchestration of V(D)J recombination.
Nat Rev Immunol. 2011;11(4):251-63.
3. Grawunder U, Harfst E. How to make ends
meet in V(D)J recombination. Curr Opin
Immunol. 2001;13(2):186-94.
4. Marculescu R, Le T, Simon P, Jaeger U, Nadel
B. V(D)J-mediated translocations in lym-
phoid neoplasms: a functional assessment of
genomic instability by cryptic sites. J Exp
Med. 2002;195(1):85-98.
5. Marculescu R, Vanura K, Montpellier B,
Roulland S, Le T, Navarro JM, et al.
Recombinase, chromosomal translocations
and lymphoid neoplasia: targeting mistakes
and repair failures. DNA Repair (Amst).
2006;5(9-10):1246-58.
6. Dik WA, Nadel B, Przybylski GK, Asnafi V,
Grabarczyk P, Navarro JM, et al. Different
chromosomal breakpoints impact the level
of LMO2 expression in T-ALL. Blood.
2007;110(1):388-92.
7. Ferrando AA, Neuberg DS, Staunton J, Loh
ML, Huard C, Raimondi SC, et al. Gene
expression signatures define novel onco-
genic pathways in T cell acute lymphoblas-
tic leukemia. Cancer Cell. 2002;1(1):75-87.
8. Bash RO, Crist WM, Shuster JJ, Link MP,
Amylon M, Pullen J, et al. Clinical features
and outcome of T-cell acute lymphoblastic
leukemia in childhood with respect to alter-
ations at the TAL1 locus: a Pediatric
Oncology Group study. Blood. 1993;81(8):
2110-7.
9. Xia Y, Brown L, Yang CY, Tsan JT, Siciliano
MJ, Espinosa R 3rd, et al. TAL2, a helix-loop-
helix gene activated by the (7;9)(q34;q32)
translocation in human T-cell leukemia. Proc
Natl Acad Sci USA. 1991;88 (24):11416-20.
10. Boehm T, Baer R, Lavenir I, Forster A,
Waters JJ, Nacheva E, et al. The mechanism
of chromosomal translocation t(11;14)
involving the T-cell receptor C delta locus on
human chromosome 14q11 and a tran-
scribed region of chromosome 11p15.
EMBO J. 1988;7(2):385-94.
11. Lin YW, Deveney R, Barbara M, Iscove NN,
Nimer SD, Slape C, et al. OLIG2 (BHLHB1),
a bHLH transcription factor, contributes to
leukemogenesis in concert with LMO1.
Cancer Res. 2005;65(16):7151-8.
12. Simonis M, Klous P, Homminga I, Galjaard
RJ, Rijkers EJ, Grosveld F, et al. High-resolu-
tion identification of balanced and complex
chromosomal rearrangements by 4C tech-
nology. Nat Methods. 2009;6(11):837-42.
13. Brake RL, Kees UR, Watt PM. Multiple neg-
ative elements contribute to repression of
the HOX11 proto-oncogene. Oncogene.
1998;17(14):1787-95.
14. Graux C, Cools J, Michaux L, Vandenberghe
P, Hagemeijer A. Cytogenetics and molecu-
lar genetics of T-cell acute lymphoblastic
leukemia: from thymocyte to lymphoblast.
Leukemia. 2006;20(9):1496-510.
15. Cave H, Suciu S, Preudhomme C, Poppe B,
Robert A, Uyttebroeck A, et al. Clinical sig-
nificance of HOX11L2 expression linked to
t(5;14)(q35;q32), of HOX11 expression, and
of SIL-TAL fusion in childhood T-cell malig-
nancies: results of EORTC studies 58881 and
58951. Blood. 2004;103(2):442-50.
16. Bergeron J, Clappier E, Cauwelier B,
Dastugue N, Millien C, Delabesse E, et al.
HOXA cluster deregulation in T-ALL associ-
ated with both a TCRD-HOXA and a
CALM-AF10 chromosomal translocation.
Leukemia. 2006;20(6):1184-7.
17. Homminga I, Pieters R, Langerak AW, de
Rooi JJ, Stubbs A, Verstegen M, et al.
Integrated transcript and genome analyses
reveal NKX2-1 and MEF2C as potential
oncogenes in T cell acute lymphoblastic
leukemia. Cancer Cell. 2011;19(4):484-97.
18. Przybylski GK, Dik WA, Grabarczyk P,
Wanzeck J, Chudobska P, Jankowski K, et al.
The effect of a novel recombination
©F
e r
ta 
St
rti 
Fo
un
da
tio
n 
N
 c
m
erc
ial
 us
between the homeobox gene NKX2-5 and
the TRD locus in T-cell acute lymphoblastic
leukemia on activation of the NKX2-5 gene.
Haematologica. 2006;91(3):317-21.
19. Ellisen LW, Bird J, West DC, Soreng AL,
Reynolds TC, Smith SD, et al. TAN-1, the
human homolog of the Drosophila notch
gene, is broken by chromosomal transloca-
tions in T lymphoblastic neoplasms. Cell.
1991;66(4):649-61.
20. Suzuki S, Nagel S, Schneider B, Chen S,
Kaufmann M, Uozumi K, et al. A second
NOTCH1 chromosome rearrangement:
t(9;14)(q34.3;q11.2) in T-cell neoplasia.
Leukemia. 2009;23(5):1003-6.
21. Clappier E, Cuccuini W, Cayuela JM,
Vecchione D, Baruchel A, Dombret H, et al.
Cyclin D2 dysregulation by chromosomal
translocations to TCR loci in T-cell acute
lymphoblastic leukemias. Leukemia. 2006;
20(1):82-6.
22. Clappier E, Cuccuini W, Kalota A,
Crinquette A, Cayuela JM, Dik WA, et al.
The C-MYB locus is involved in chromoso-
mal translocation and genomic duplications
in human T-cell acute leukemia (T-ALL), the
translocation defining a new T-ALL subtype
in very young children. Blood. 2007;110(4):
1251-61.
23. Burnett RC, Thirman MJ, Rowley JD, Diaz
MO. Molecular analysis of the T-cell acute
lymphoblastic leukemia-associated
t(1;7)(p34;q34) that fuses LCK and TCRB.
Blood. 1994;84(4):1232-6.
24. Przybylski GK, Dik WA, Wanzeck J,
Grabarczyk P, Majunke S, Martin-Subero JI,
et al. Disruption of the BCL11B gene
through inv(14)(q11.2q32.31) results in the
expression of BCL11B-TRDC fusion tran-
scripts and is associated with the absence of
wild-type BCL11B transcripts in T-ALL.
Leukemia. 2005;19(2):201-8.
25. Russo G, Isobe M, Pegoraro L, Finan J,
Nowell PC, Croce CM. Molecular analysis
of a t(7;14)(q35;q32) chromosome transloca-
tion in a T cell leukemia of a patient with
ataxia telangiectasia. Cell. 1988;53(1):137-
44.
26. Bertness VL, Felix CA, McBride OW,
Morgan R, Smith SD, Sandberg AA, et al.
Characterization of the breakpoint of a
t(14;14)(q11.2;q32) from the leukemic cells
of a patient with T-cell acute lymphoblastic
leukemia. Cancer Genet Cytogenet. 1990;
44(1):47-54.
27. Larmonie NS, Dik WA, Beverloo HB, van
Wering ER, van Dongen JJ, Langerak AW.
BMI1 as oncogenic candidate in a novel
TCRB-associated chromosomal aberration
in a patient with TCRgammadelta+ T-cell
acute lymphoblastic leukemia. Leukemia.
2008;22(6):1266-7.
28. Messier TL, O'Neill JP, Finette BA. V(D)J
recombinase mediated inter-chromosomal
HPRT alterations at cryptic recombination
signal sequences in peripheral human T
cells. Hum Mutat. 2006;27(8):829.
29. Breit TM, Mol EJ, Wolvers-Tettero IL,
Ludwig WD, van Wering ER, van Dongen JJ.
Site-specific deletions involving the tal-1 and
sil genes are restricted to cells of the T cell
receptor alpha/beta lineage: T cell receptor
delta gene deletion mechanism affects mul-
tiple genes. J Exp Med. 1993;177(4):965-77.
30. Finette BA. Analysis of mutagenic V(D)J
recombinase mediated mutations at the
HPRT locus as an in vivo model for studying
rearrangements with leukemogenic poten-
tial in children. DNA Repair (Amst). 2006;5
(9-10):1049-64.
31. Raghavan SC, Kirsch IR, Lieber MR.
Analysis of the V(D)J recombination effi-
ciency at lymphoid chromosomal transloca-
tion breakpoints. J Biol Chem. 2001;276
(31):29126-33.
32. Vanura K, Vrsalovic MM, Le T, Marculescu
R, Kusec R, Jager U, et al. V(D)J targeting
mistakes occur at low frequency in acute
lymphoblastic leukemia. Genes
Chromosomes Cancer. 2009;48(8):725-36.
33. Fitzgerald TJ, Neale GA, Raimondi SC,
Goorha RM. Rhom-2 expression does not
always correlate with abnormalities on
chromosome 11 at band p13 in T-cell acute
lymphoblastic leukemia. Blood. 1992;80(12):
3189-97.
34. Yoffe G, Schneider N, Van Dyk L, Yang CY,
Siciliano M, Buchanan G, et al. The chromo-
some translocation (11;14)(p13;q11) associ-
ated with T-cell acute lymphocytic
leukemia: an 11p13 breakpoint cluster
region. Blood. 1989;74(1):374-9.
35. Cheng JT, Yang CY, Hernandez J, Embrey J,
Baer R. The chromosome translocation
(11;14)(p13;q11) associated with T cell acute
leukemia. Asymmetric diversification of the
translocational junctions. J Exp Med. 1990;
171(2):489-501.
36. Champagne E, Takihara Y, Sagman U, de
Sousa J, Burrow S, Lewis WH, et al. The T-
cell receptor delta chain locus is disrupted in
the T-ALL associated t(11;14)(p13;q11)
translocation. Blood. 1989;73(6):1672-6.
37. Boehm T, Buluwela L, Williams D, White L,
Rabbitts TH. A cluster of chromosome
11p13 translocations found via distinct D-D
and D-D-J rearrangements of the human T
cell receptor delta chain gene. EMBO J.
1988;7(7):2011-7.
38. Chen Q, Cheng JT, Tasi LH, Schneider N,
Buchanan G, Carroll A, et al. The tal gene
undergoes chromosome translocation in T
cell leukemia and potentially encodes a
helix-loop-helix protein. EMBO J. 1990;
9(2):415-24.
39. Jonsson OG, Kitchens RL, Baer RJ, Buchanan
GR, Smith RG. Rearrangements of the tal-1
locus as clonal markers for T cell acute lym-
phoblastic leukemia. J Clin Invest. 1991;87
(6):2029-35.
40. Bernard O, Barin C, Charrin C, Mathieu-
Mahul D, Berger R. Characterization of
translocation t(1;14)(p32;q11) in a T and in a
B acute leukemia. Leukemia. 1993;7(10):
1509-13.
41. Chen Q, Yang CY, Tsan JT, Xia Y, Ragab AH,
Peiper SC, et al. Coding sequences of the tal-
1 gene are disrupted by chromosome
translocation in human T cell leukemia. J
Exp Med. 1990;172(5):1403-8.
42. Bernard O, Azogui O, Lecointe N, Mugneret
F, Berger R, Larsen CJ, et al. A third tal-1 pro-
moter is specifically used in human T cell
leukemias. J Exp Med. 1992;176(4):919-25.
43. Begley CG, Aplan PD, Davey MP, Nakahara
K, Tchorz K, Kurtzberg J, et al.
Chromosomal translocation in a human
leukemic stem-cell line disrupts the T-cell
antigen receptor delta-chain diversity region
and results in a previously unreported fusion
transcript. Proc Natl Acad Sci USA. 1989;
86(6):2031-5.
44. Finger LR, Kagan J, Christopher G,
Kurtzberg J, Hershfield MS, Nowell PC, et
al. Involvement of the TCL5 gene on human
chromosome 1 in T-cell leukemia and
melanoma. Proc Natl Acad Sci USA. 1989;
86(13):5039-43.
45. Fitzgerald TJ, Neale GA, Raimondi SC,
Goorha RM. c-tal, a helix-loop-helix protein,
is juxtaposed to the T-cell receptor-beta
chain gene by a reciprocal chromosomal
translocation: t(1;7)(p32;q35). Blood. 1991;
78(10):2686-95.
46. Dadi S, Le Noir S, Payet-Bornet D, Lhermitte
L, Zacarias-Cabeza J, Bergeron J, et al. TLX
homeodomain oncogenes mediate T cell
maturation arrest in T-ALL via interaction
with ETS1 and suppression of TCRalpha
gene expression. Cancer Cell. 2012;21(4):
563-76.
47. Lu M, Gong ZY, Shen WF, Ho AD. The tcl-3
proto-oncogene altered by chromosomal
translocation in T-cell leukemia codes for a
homeobox protein. EMBO J. 1991;10(10):
2905-10.
48. Salvati PD, Watt PM, Thomas WR, Kees UR.
Molecular characterization of a complex
chromosomal translocation breakpoint
t(10;14) including the HOX11 oncogene
locus. Leukemia. 1999;13(6):975-9.
49. Kagan J, Joe YS, Freireich EJ. Joining of
recombination signals on the der 14q- chro-
mosome in T-cell acute leukemia with
t(10;14) chromosome translocation. Cancer
Res. 1994;54(1):226-30.
50. Kagan J, Finger LR, Letofsky J, Finan J,
Nowell PC, Croce CM. Clustering of break-
points on chromosome 10 in acute T-cell
leukemias with the t(10;14) chromosome
translocation. Proc Natl Acad Sci USA. 1989;
86(11):4161-5.
51. Zutter M, Hockett RD, Roberts CW,
McGuire EA, Bloomstone J, Morton CC, et
al. The t(10;14)(q24;q11) of T-cell acute lym-
phoblastic leukemia juxtaposes the delta T-
cell receptor with TCL3, a conserved and
activated locus at 10q24. Proc Natl Acad Sci
USA. 1990;87(8):3161-5.
52. Soulier J, Clappier E, Cayuela JM, Regnault
A, Garcia-Peydro M, Dombret H, et al.
HOXA genes are included in genetic and
biologic networks defining human acute T-
cell leukemia (T-ALL). Blood. 2005;106
(1):274-86.
53. Tycko B, Smith SD, Sklar J. Chromosomal
translocations joining LCK and TCRB loci in
human T cell leukemia. J Exp Med.
1991;174(4):867-73.
54. Homminga I, Vuerhard MJ, Langerak AW,
Buijs-Gladdines J, Pieters R, Meijerink JP.
Characterization of a pediatric T-cell acute
lymphoblastic leukemia patient with simul-
taneous LYL1 and LMO2 rearrangements.
Haematologica. 2012;97(2):258-61.
55. McGuire EA, Hockett RD, Pollock KM,
Bartholdi MF, O'Brien SJ, Korsmeyer SJ. The
t(11;14)(p15;q11) in a T-cell acute lym-
phoblastic leukemia cell line activates multi-
ple transcripts, including Ttg-1, a gene
encoding a potential zinc finger protein. Mol
Cell Biol. 1989;9(5):2124-32.
56. Cleary ML, Mellentin JD, Spies J, Smith SD.
Chromosomal translocation involving the
beta T cell receptor gene in acute leukemia. J
Exp Med. 1988;167(2):682-7.
57. Bernard O, Larsen CJ, Hampe A,
Mauchauffe M, Berger R, Mathieu-Mahul
D. Molecular mechanisms of a
t(8;14)(q24;q11) translocation juxtaposing c-
myc and TcR-alpha genes in a T-cell
leukaemia: involvement of a V alpha internal
heptamer. Oncogene. 1988;2(2):195-200.
58. Shima-Rich EA, Harden AM, McKeithan
TW, Rowley JD, Diaz MO. Molecular analy-
sis of the t(8;14)(q24;q11) chromosomal
breakpoint junctions in the T-cell leukemia
line MOLT-16. Genes Chromosomes
Cancer. 1997;20(4):363-71.
59. Finger LR, Harvey RC, Moore RC, Showe
LC, Croce CM. A common mechanism of
chromosomal translocation in T- and B-cell
neoplasia. Science. 1986;234(4779):982-5.
60. Kasai M, Maziarz RT, Aoki K, Macintyre E,
Strominger JL. Molecular involvement of the
pvt-1 locus in a gamma/delta T-cell leukemia
V(D)J recombination role in (non) TCR aberrations
haematologica | 2013; 98(8) 1183
©F
err
at
 S
tor
ti F
ou
nd
ati
 
No
co
mm
rci
al 
us
e
bearing a variant t(8;14)(q24;q11) transloca-
tion. Mol Cell Biol. 1992;12(10):4751-7.
61. Park JK, McKeithan TW, Le Beau MM, Bitter
MA, Franklin WA, Rowley JD, et al. An
(8;14)(q24;q11) translocation involving the
T-cell receptor alpha-chain gene and the
MYC oncogene 3' region in a B-cell lym-
phoma. Genes Chromosomes Cancer. 1989;
1(1):15-22.
62. Reynolds TC, Smith SD, Sklar J. Analysis of
DNA surrounding the breakpoints of chro-
mosomal translocations involving the beta T
cell receptor gene in human lymphoblastic
neoplasms. Cell. 1987;50(1):107-17.
63. Palomero T, Barnes KC, Real PJ, Glade
Bender JL, Sulis ML, Murty VV, et al.
CUTLL1, a novel human T-cell lymphoma
cell line with t(7;9) rearrangement, aberrant
NOTCH1 activation and high sensitivity to
gamma-secretase inhibitors. Leukemia.
2006;20(7):1279-87.
64. Wang J, Jani-Sait SN, Escalon EA, Carroll AJ,
de Jong PJ, Kirsch IR, et al. The
t(14;21)(q11.2;q22) chromosomal transloca-
tion associated with T-cell acute lym-
phoblastic leukemia activates the BHLHB1
gene. Proc Natl Acad Sci USA. 2000;97
(7):3497-502.
65. Tycko B, Reynolds TC, Smith SD, Sklar J.
Consistent breakage between consensus
recombinase heptamers of chromosome 9
DNA in a recurrent chromosomal transloca-
tion of human T cell leukemia. J Exp Med.
1989;169(2):369-77.
66. Hansen-Hagge TE, Schafer M, Kiyoi H,
Morris SW, Whitlock JA, Koch P, et al.
Disruption of the RanBP17/Hox11L2 region
by recombination with the TCRdelta locus
in acute lymphoblastic leukemias with
t(5;14)(q34;q11). Leukemia. 2002;16(11):
2205-12.
67. Lemaitre C, Zaghloul L, Sagot MF, Gautier
C, Arneodo A, Tannier E, et al. Analysis of
fine-scale mammalian evolutionary break-
points provides new insight into their rela-
tion to genome organisation. BMC
Genomics. 2009;10:335.
68. Le Noir S, Ben Abdelali R, Lelorch M,
Bergeron J, Sungalee S, Payet-Bornet D, et al.
Extensive molecular mapping of
TCRalpha/delta and TCRbeta involved
chromosomal translocations reveals distinct
mechanisms of oncogenes activation in T-
ALL. Blood. 2012;120(16):3298-309.
69. Allam A, Kabelitz D. TCR trans-rearrange-
ments: biological significance in antigen
recognition vs the role as lymphoma bio-
marker. J Immunol. 2006;176(10):5707-12.
70. Lipkowitz S, Stern MH, Kirsch IR. Hybrid T
cell receptor genes formed by interlocus
recombination in normal and ataxia-telang-
iectasis lymphocytes. J Exp Med. 1990;172
(2):409-18.
71. Campese AF, Garbe AI, Zhang F, Grassi F,
Screpanti I, von Boehmer H. Notch1-depen-
dent lymphomagenesis is assisted by but
does not essentially require pre-TCR signal-
ing. Blood. 2006;108(1):305-10.
72. Ferrero I, Mancini SJ, Grosjean F, Wilson A,
Otten L, MacDonald HR. TCRgamma
silencing during alphabeta T cell develop-
ment depends upon pre-TCR-induced pro-
liferation. J Immunol. 2006;177(9):6038-43.
73. Hahn WC, Weinberg RA. Rules for making
human tumor cells. N Engl J Med. 2002;347
(20):1593-603.
74. Merelli I, Guffanti A, Fabbri M, Cocito A,
Furia L, Grazini U, et al. RSSsite: a reference
database and prediction tool for the identifi-
cation of cryptic Recombination Signal
Sequences in human and murine genomes.
Nucleic Acids Res. 2010;38(Web Server
issue):W262-7.
75. Ji Y, Little AJ, Banerjee JK, Hao B, Oltz EM,
Krangel MS, et al. Promoters, enhancers, and
transcription target RAG1 binding during
V(D)J recombination. J Exp Med. 2010;207
(13):2809-16.
76. Schlissel MS. Epigenetics drives RAGs to
recombination riches. Cell. 2010;141(3):400-
2.
77. Nishana M, Raghavan SC. A non-B DNA
can replace heptamer of V(D)J recombina-
tion when present along with a nonamer:
implications in chromosomal translocations
and cancer. Biochem J. 2012;448(1):115-25.
78. De S, Michor F. DNA secondary structures
and epigenetic determinants of cancer
genome evolution. Nat Struct Mol Biol.
2011;18(8):950-5.
79. Zhao J, Bacolla A, Wang G, Vasquez KM.
Non-B DNA structure-induced genetic insta-
bility and evolution. Cell Mol Life Sci.
2010;67(1):43-62.
80. van Zelm MC, Geertsema C, Nieuwenhuis
N, de Ridder D, Conley ME, Schiff C, et al.
Gross deletions involving IGHM, BTK, or
Artemis: a model for genomic lesions medi-
ated by transposable elements. Am J Hum
Genet. 2008;82(2):320-32.
81. Fullerton SM, Bernardo Carvalho A, Clark
AG. Local rates of recombination are posi-
tively correlated with GC content in the
human genome. Mol Biol Evol. 2001;18
(6):1139-42.
82. Zhang Y, Rowley JD. Chromatin structural
elements and chromosomal translocations in
leukemia. DNA Repair (Amst). 2006;5(9-
10):1282-97.
83. Deriano L, Chaumeil J, Coussens M,
Multani A, Chou Y, Alekseyenko AV, et al.
The RAG2 C terminus suppresses genomic
instability and lymphomagenesis. Nature.
2011;471(7336):119-23.
84. Marculescu R, Vanura K, Le T, Simon P, Jager
U, Nadel B. Distinct t(7;9)(q34;q32) break-
points in healthy individuals and individuals
with T-ALL. Nat Genet. 2003;33(3):342-4.
85. Breit TM, Verschuren MC, Wolvers-Tettero
IL, Van Gastel-Mol EJ, Hahlen K, van
Dongen JJ. Human T cell leukemias with
continuous V(D)J recombinase activity for
TCR-delta gene deletion. J Immunol.
1997;159(9):4341-9.
86. Arnal SM, Holub AJ, Salus SS, Roth DB.
Non-consensus heptamer sequences desta-
bilize the RAG post-cleavage complex, mak-
ing ends available to alternative DNA repair
pathways. Nucleic Acids Res. 2010;38(9):
2944-54.
87. Lee GS, Neiditch MB, Salus SS, Roth DB.
RAG proteins shepherd double-strand
breaks to a specific pathway, suppressing
error-prone repair, but RAG nicking initiates
homologous recombination. Cell. 2004;117
(2):171-84.
88. Shiloh Y. Ataxia-telangiectasia and the
Nijmegen breakage syndrome: related disor-
ders but genes apart. Annu Rev Genet.
1997;31:635-62.
89. van der Burgt I, Chrzanowska KH, Smeets
D, Weemaes C. Nijmegen breakage syn-
drome. J Med Genet. 1996;33(2):153-6.
90. Isoda T, Takagi M, Piao J, Nakagama S, Sato
M, Masuda K, et al. Process for immune
defect and chromosomal translocation dur-
ing early thymocyte development lacking
ATM. Blood. 2012;120(4):789-99.
91. Zha S, Bassing CH, Sanda T, Brush JW, Patel
H, Goff PH, et al. ATM-deficient thymic
lymphoma is associated with aberrant tcrd
rearrangement and gene amplification. J Exp
Med. 2010;207(7):1369-80.
92. Petiniot LK, Weaver Z, Vacchio M, Shen R,
Wangsa D, Barlow C, et al. RAG-mediated
V(D)J recombination is not essential for
tumorigenesis in Atm-deficient mice. Mol
Cell Biol. 2002;22(9):3174-7.
93. Szczepanski T, Pongers-Willemse MJ,
Langerak AW, Harts WA, Wijkhuijs AJ, van
Wering ER, et al. Ig heavy chain gene
rearrangements in T-cell acute lymphoblas-
tic leukemia exhibit predominant DH6-19
and DH7-27 gene usage, can result in com-
plete V-D-J rearrangements, and are rare in
T-cell receptor alpha beta lineage. Blood.
1999;93(12):4079-85.
94. Szczepanski T, Pongers-Willemse MJ,
Langerak AW, van Dongen JJ. Unusual
immunoglobulin and T-cell receptor gene
rearrangement patterns in acute lymphoblas-
tic leukemias. Curr Top Microbiol Immunol.
1999;246:205-13; discussion 214-5.
95. Rainville IR, Albertini RJ, Nicklas JA.
Breakpoints and junctional regions of intra-
genic deletions in the HPRT gene in human
T-Cells. Somat Cell Mol Genet. 1995;21
(5):309-26.
96. Messier TL, O'Neill JP, Hou SM, Nicklas JA,
Finette BA. In vivo transposition mediated
by V(D)J recombinase in human T lympho-
cytes. EMBO J. 2003;22(6):1381-8.
97. Aplan PD, Lombardi DP, Reaman GH,
Sather HN, Hammond GD, Kirsch IR.
Involvement of the putative hematopoietic
transcription factor SCL in T-cell acute lym-
phoblastic leukemia. Blood. 1992;79(5):
1327-33.
98. Van Vlierberghe P, van Grotel M, Beverloo
HB, Lee C, Helgason T, Buijs-Gladdines J, et
al. The cryptic chromosomal deletion
del(11)(p12p13) as a new activation mecha-
nism of LMO2 in pediatric T-cell acute lym-
phoblastic leukemia. Blood. 2006;108(10):
3520-9.
99. Fuscoe JC, Zimmerman LJ, Lippert MJ,
Nicklas JA, O'Neill JP, Albertini RJ. V(D)J
recombinase-like activity mediates hprt
gene deletion in human fetal T-lympho-
cytes. Cancer Res. 1991;51(21):6001-5.
100.Bertocci B, De Smet A, Weill JC, Reynaud
CA. Nonoverlapping functions of DNA
polymerases mu, lambda, and terminal
deoxynucleotidyltransferase during
immunoglobulin V(D)J recombination in
vivo. Immunity. 2006;25(1):31-41.
N.S.D. Larmonie et al.
1184 haematologica | 2013; 98(8)
©F
er
ta 
St
ort
i F
ou
nd
t
 
No
 c
mm
erc
i l
 us
